Screening G6PD mutation in blood donors by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry with high-throughput and multiple targets.
{"title":"Screening G6PD mutation in blood donors by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry with high-throughput and multiple targets.","authors":"Ziyan Li, Zhenyi Huang, Mengxi Li, Yunshan Cao, Yating Li, Jinlv Liu, Suping Zhong, Lijuan Lin, Yanping Fang, Zhaoying Su, Yongxin Huang, Wanjun Zhou, Lingxiao Jiang","doi":"10.1016/j.jmoldx.2025.05.004","DOIUrl":null,"url":null,"abstract":"<p><p>Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited disorder worldwide and is particularly prevalent in historically malaria-endemic countries. In this study, we established a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) assay for G6PD mutation detection. This MALDI-TOF-MS assay with single base extension (SBE) was developed to efficiently and accurately test 19 common G6PD variants in the Chinese population. The MALDI-TOF-MS assay was used to analyze a total of 2,205 peripheral blood samples, including 1,111 normal individuals and 1,094 G6PD gene mutation carriers. All 2,205 sample results were validated by Sanger sequencing in a blinded study. The MALDI-TOF-MS assay developed in this study was applied to detect G6PD mutations in 300 uncharacterized blood donor samples, of which 17 (5.56%) were found to carry G6PD gene mutations. Basic characteristics of regarding the 17 blood donors were summarized and followed up. In this study, a MALDI-TOF-MS assay was applied to blood donors to detect common G6PD mutations in Guangdong, China, which provided a new concept for establishing the information regarding the blood bank database of G6PD deficiency donors.</p>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jmoldx.2025.05.004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited disorder worldwide and is particularly prevalent in historically malaria-endemic countries. In this study, we established a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) assay for G6PD mutation detection. This MALDI-TOF-MS assay with single base extension (SBE) was developed to efficiently and accurately test 19 common G6PD variants in the Chinese population. The MALDI-TOF-MS assay was used to analyze a total of 2,205 peripheral blood samples, including 1,111 normal individuals and 1,094 G6PD gene mutation carriers. All 2,205 sample results were validated by Sanger sequencing in a blinded study. The MALDI-TOF-MS assay developed in this study was applied to detect G6PD mutations in 300 uncharacterized blood donor samples, of which 17 (5.56%) were found to carry G6PD gene mutations. Basic characteristics of regarding the 17 blood donors were summarized and followed up. In this study, a MALDI-TOF-MS assay was applied to blood donors to detect common G6PD mutations in Guangdong, China, which provided a new concept for establishing the information regarding the blood bank database of G6PD deficiency donors.
期刊介绍:
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology (AMP), co-owned by the American Society for Investigative Pathology (ASIP), seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, clinical informatics, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods which may be applied to diagnosis or monitoring of disease or disease predisposition.